HWM
REGN icon

HB Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

HB Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
2,712
-724
-21% -$493K 0.01% 525
2026
Q1 		$2.66M Buy
3,436
+1,009
+42% +$772K 0.02% 373
2025
Q4 		$1.87M Buy
2,427
+646
+36% +$439K 0.01% 421
2025
Q3 		$1M Sell
1,781
-268
-13% -$152K 0.01% 604
2025
Q2 		$1.08M Buy
2,049
+46
+2% +$25.7K 0.01% 516
2025
Q1 		$1.27M Sell
2,003
-126
-6% -$86.7K 0.01% 483
2024
Q4 		$1.52M Buy
2,129
+161
+8% +$135K 0.02% 335
2024
Q3 		$2.07M Buy
1,968
+116
+6% +$129K 0.02% 272
2024
Q2 		$1.95M Buy
1,852
+181
+11% +$175K 0.02% 269
2024
Q1 		$1.61M Buy
1,671
+552
+49% +$525K 0.02% 281
2023
Q4 		$983K Buy
1,119
+212
+23% +$175K 0.01% 320
2023
Q3 		$746K Buy
907
+199
+28% +$156K 0.01% 345
2023
Q2 		$509K Buy
708
+6
+0.9% +$4.63K 0.01% 412
2023
Q1 		$577K Buy
702
+154
+28% +$116K 0.01% 380
2022
Q4 		$395K Buy
548
+135
+33% +$99.6K 0.01% 450
2022
Q3 		$285K Buy
+413
New +$260K 0.01% 452

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HB Wealth Management's REGN Position: Q2 2026 in Review

HB Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 21% in Q2 2026, selling an estimated $493K and leaving 2,712 shares worth $1.69M. The position accounts for 0.01% of the portfolio, ranked #525.

HB Wealth Management first reported a position in REGN in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.66M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • HB Wealth Management held 2,712 shares of Regeneron Pharmaceuticals worth $1.69M as of Q2 2026.
  • HB Wealth Management sold 724 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $493K.
  • Regeneron Pharmaceuticals made up 0.01% of HB Wealth Management's portfolio in Q2 2026, its #525 holding.
  • HB Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • HB Wealth Management's Regeneron Pharmaceuticals position peaked at $2.66M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.